Summit Therapeutics Files 8-K Report

Ticker: SMMT · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1599298

Summit Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanySummit Therapeutics Inc. (SMMT)
Form Type8-K
Filed DateSep 9, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, regulatory

TL;DR

Summit Therapeutics filed an 8-K, standard procedure, no major news yet.

AI Summary

On September 8, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates ongoing reporting requirements for Summit Therapeutics Inc. to the SEC, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report without immediate disclosure of significant new risks or material adverse events.

Key Players & Entities

  • Summit Therapeutics Inc. (company) — Registrant
  • September 8, 2024 (date) — Date of Earliest Event Reported
  • Delaware (jurisdiction) — State of Incorporation
  • 001-36866 (identifier) — Commission File Number
  • 37-1979717 (identifier) — IRS Employer Identification No.
  • 601 Brickell Key Drive, Suite 1000, Miami, FL 33131 (address) — Address of Principal Executive Offices
  • (305) 203-2034 (phone_number) — Registrant's Telephone Number

FAQ

What is the primary purpose of this 8-K filing for Summit Therapeutics Inc.?

The filing serves as a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is September 8, 2024.

In which U.S. state is Summit Therapeutics Inc. incorporated?

Summit Therapeutics Inc. is incorporated in Delaware.

What is the Commission File Number for Summit Therapeutics Inc.?

The Commission File Number for Summit Therapeutics Inc. is 001-36866.

What is the address of Summit Therapeutics Inc.'s Principal Executive Offices?

The address of Summit Therapeutics Inc.'s Principal Executive Offices is 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.

Filing Stats: 867 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2024-09-09 07:23:04

Key Financial Figures

  • $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Summit Therapeutics Inc. (the "Company") announced data relating to the HARMONi-2 trial, conducted in China and sponsored by our collaboration partner, Akeso, Inc. (Akeso, HKEX Code: 9926.HK) ("Akeso"), with data generated and analyzed by Akeso. The data was presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer's ("IASLC") 2024 World Conference on Lung Cancer ("WCLC 2024") by Dr. Caicun Zhou, Chief Physician and Director of the Department of Medical Oncology at Shanghai Pulmonary Hospital, Tongji University School of Medicine, and President-Elect of IASLC on September 8, 2024. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. Additionally, the Company announced data relating to the Phase II trial, AK112-205 ("AK112-205"), which was conducted and sponsored by Akeso, featuring data from ivonescimab in the perioperative, early-stage NSCLC setting. The data was also announced at WCLC 2024 by Dr. Xiaoliang Zhao, Deputy Chief Physician, Department of Lung Cancer at Tianjin Medical University Cancer Institute & Hospital, and Visiting Scholar at the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K. Finally, data abstracts in three additional Phase II clinical trials were released by European Society of Medical Oncology ("ESMO"). This included Phase II data from clinical studies sponsored by Akeso in first-line triple negative advanced breast cancer, first-line advanced colorectal cancer, and first-line head-and-neck squamous cell carcinoma. The Company will utilize slides during its conference call scheduled for 8:30am ET on September 9, 2024 discussing the datasets associated with HARMONi-2, AK112-205 and the additional Phase II clinical trials. A copy of the slides is furnished as Exhibit 99.3 to this Current Rep

01 Other Events

Item 8.01 Other Events. On September 8, 2024, the Company issued a press release announcing the datasets associated with HARMONi-2 and AK112-205. A copy of the September 8, 2024 press release is attached as Exhibit 99.4 to this Current Report on Form 8-K and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 WCLC 2024 Presentation on HARMONi-2 Data 99.2 WCLC 2024 Presentation on Phase II trial, AK112-205 Data 99.3 P resentation Sli des for September 9, 2 024 Conference Call 99.4 Press release, dated September 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: September 9, 2024 By: /s/ Manmeet S. Soni Chief Operating Officer and Chief Financial Officer (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.